Authorized purpose: Opulus Lymphoma Precision segments and visualizes lesions and measures total metabolic tumor volume in whole-body FDG-PET/CT for patients already diagnosed with FDG-avid lymphoma; trained physicians can accept/reject annotated output, but radiologist review makes the final interpretation and the device is not a screening/diagnostic substitute.
Clinical role
Segmentation, visualization, and volumetric measurement support
Images and patients
PET/SPECT/Nuclear Medicine · Whole-body FDG-PET/CT
Key limitation
Keep in mind: The device is assistive for already diagnosed FDG-avid lymphoma, is not a screening tool or diagnostic substitute, and requires trained physician review and final interpretation.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Opulus Lymphoma Precision segments and visualizes lesions and measures total metabolic tumor volume in whole-body FDG-PET/CT for patients already diagnosed with FDG-avid lymphoma; trained physicians can accept/reject annotated output, but radiologist review makes the final interpretation and the device is not a screening/diagnostic substitute.
Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Whole-body FDG-PET/CT Input: Whole-body FDG-PET/CT in standard DICOM format, consisting of PET with associated attenuation-correction CT, from patients with pathologically diagnosed FDG-avid lymphoma.
Who uses it?Intended users: Trained interpreting physicians, including radiologists and nuclear medicine physicians
What does the software produce?Output: Localization and segmentation of FDG-avid lesions, overlay visualization, segmentation masks, a total metabolic tumor volume measurement, and a report/image overlay; the physician may accept or reject the algorithm output but cannot modify it.
What is its most important limitation?Key limitation: The device is assistive for already diagnosed FDG-avid lymphoma, is not a screening tool or diagnostic substitute, and requires trained physician review and final interpretation.
Clinical takeaway. Clinical role: Opulus Lymphoma Precision segments and visualizes lesions and measures total metabolic tumor volume in whole-body FDG-PET/CT for patients already diagnosed with FDG-avid lymphoma; trained physicians can accept/reject annotated output, but radiologist review makes the final interpretation and the device is not a screening/diagnostic substitute.
Evidence takeaway. Evidence from the reviewed source record: Test-set validation used 182 unique patients across multiple geographies and PET/CT vendors; the FDA compares cube-root-transformed total metabolic tumor volume differences in centimeters, using a 2.5 cm threshold on that transformed scale, against a reference generated by nine radiologists and nuclear medicine physicians.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Opulus Lymphoma Precision segments and visualizes lesions and measures total metabolic tumor volume in whole-body FDG-PET/CT for patients already diagnosed with FDG-avid lymphoma; trained physicians can accept/reject annotated output, but radiologist review makes the final interpretation and the device is not a screening/diagnostic substitute.
Whole-body FDG-PET/CT in standard DICOM format, consisting of PET with associated attenuation-correction CT, from patients with pathologically diagnosed FDG-avid lymphoma.
Localization and segmentation of FDG-avid lesions, overlay visualization, segmentation masks, a total metabolic tumor volume measurement, and a report/image overlay; the physician may accept or reject the algorithm output but cannot modify it.
The device is assistive for already diagnosed FDG-avid lymphoma, is not a screening tool or diagnostic substitute, and requires trained physician review and final interpretation.
Test-set validation used 182 unique patients across multiple geographies and PET/CT vendors; the FDA compares cube-root-transformed total metabolic tumor volume differences in centimeters, using a 2.5 cm threshold on that transformed scale, against a reference generated by nine radiologists and nuclear medicine physicians.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Test-set validation used 182 unique patients across multiple geographies and PET/CT vendors; the FDA compares cube-root-transformed total metabolic tumor volume differences in centimeters, using a 2.5 cm threshold on that transformed scale, against a reference generated by nine radiologists and nuclear medicine physicians.
Opulus Lymphoma Precision TMTV and segmentation validation
DesignRetrospective test-set validation against pooled physician reference
Population182 unique patients from multiple geographies and GE, Siemens, and Philips PET/CT systems
Scopeexact submission
Tested versionOpulus Lymphoma Precision submitted in K243863; build not stated
Samplen=182
IndependenceIndependence not established
K243863
The FDA describes the test data as independent from training data; reference pool comprised nine radiologists and nuclear medicine physicians. Independence of investigators or sponsorship was not established. TMTV differences are on the cube-root-transformed scale, with the 2.5 cm group threshold on that scale.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Whole-body FDG-PET/CT in standard DICOM format, consisting of PET with associated attenuation-correction CT, from patients with pathologically diagnosed FDG-avid lymphoma.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The submission describes standard DICOM PET/CT input, report generation, and image/segmentation-mask overlays; current PACS/workstation routing and deployment architecture were not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources establish DICOM image-processing function and commercial distribution, but not a current hosting model or regional data flow.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-07 ·
Returned objects
Source context, not route validation: Localization and segmentation of FDG-avid lesions, overlay visualization, segmentation masks, a total metabolic tumor volume measurement, and a report/image overlay; the physician may accept or reject the algorithm output but cannot modify it.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Localization and segmentation of FDG-avid lesions, overlay visualization, segmentation masks, a total metabolic tumor volume measurement, and a report/image overlay; the physician may accept or reject the algorithm output but cannot modify it.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The submission describes standard DICOM PET/CT input, report generation, and image/segmentation-mask overlays; current PACS/workstation routing and deployment architecture were not established.
AccessGUDID lists Opulus Lymphoma Precision as a DICOM image-processing software device and records it as in commercial distribution; the current hosting model and local integration are not documented there.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
No stored PubMed or ClinicalTrials.gov candidate identifiers for this submission in the 2026-09-01 snapshot; exact-submission recall candidate review was also zero. This metadata screen is not a full paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, government device registry, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission
No public amount, range, currency, geography, or contract term was established.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Opulus Lymphoma Precision Roche reimbursement"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. The Roche page read describes a lab-assay reimbursement portal and does not name this product. This records what was found, not that none exists.
Deployment: Not verified - checked 2026-09-07 - Exact FDA submission
The reviewed sources establish DICOM image-processing function and commercial distribution, but not a current hosting model or regional data flow.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-07 - Exact FDA submission
No scoped current security, data-flow, access-control, retention, or incident-response documentation was established.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-07 - Exact FDA submission
Current onboarding, competency, and support commitments were not established.
Monitoring: Not verified - checked 2026-09-07 - Exact FDA submission
Local acceptance testing, production monitoring, update control, and drift review were not established.
Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.
Authorized purpose: uMI Panorama combines PET and CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and fused PET/CT images for qualified healthcare professionals supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation across oncology, cardiology, neurology, and other disorders; its CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.
Authorized purpose: uMI Panorama GS combines 148 cm axial-field-of-view PET with CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and registered or fused PET/CT images supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation in oncology, cardiology, neurology, inflammation, infection, and other disorders. The CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.